CD274 and Marinesco-Sjogren syndrome: Colorectal cancer with MSS has long been considered resistant to PD-1/PD-L1 blockade.2,3,4,5 However, the promising response rate of 33% seen in the Japanese REGONIVO trial6 has revitalized interest in immunotherapy in MSS colorectal cancer.